Cited 31 times in
Drug-eluting stents to prevent stent thrombosis and restenosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 임의 | - |
dc.contributor.author | 홍명기 | - |
dc.date.accessioned | 2017-01-19T12:57:55Z | - |
dc.date.available | 2017-01-19T12:57:55Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1477-9072 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/145509 | - |
dc.description.abstract | Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format.extent | 87~104 | - |
dc.language | English | - |
dc.publisher | Taylor & Francis | - |
dc.relation.isPartOf | EXPERT REVIEW OF CARDIOVASCULAR THERAPY | - |
dc.subject.MESH | Absorbable Implants | - |
dc.subject.MESH | Coated Materials, Biocompatible/pharmacology | - |
dc.subject.MESH | Coronary Restenosis*/etiology | - |
dc.subject.MESH | Coronary Restenosis*/prevention & control | - |
dc.subject.MESH | Drug-Eluting Stents*/adverse effects | - |
dc.subject.MESH | Drug-Eluting Stents*/standards | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacology | - |
dc.subject.MESH | Inventions | - |
dc.subject.MESH | Percutaneous Coronary Intervention/instrumentation* | - |
dc.subject.MESH | Polymers/pharmacology | - |
dc.subject.MESH | Postoperative Complications/prevention & control* | - |
dc.subject.MESH | Randomized Controlled Trials as Topic | - |
dc.subject.MESH | Sirolimus*/analogs & derivatives | - |
dc.subject.MESH | Sirolimus*/pharmacology | - |
dc.subject.MESH | Thrombosis*/etiology | - |
dc.subject.MESH | Thrombosis*/prevention & control | - |
dc.title | Drug-eluting stents to prevent stent thrombosis and restenosis | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Eui Im | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.identifier.doi | 10.1586/14779072.2016.1112267 | - |
dc.contributor.localId | A03394 | - |
dc.contributor.localId | A04391 | - |
dc.relation.journalcode | J00879 | - |
dc.identifier.eissn | 1744-8344 | - |
dc.identifier.pmid | 26567863 | - |
dc.identifier.url | http://www.tandfonline.com/doi/full/10.1586/14779072.2016.1112267 | - |
dc.subject.keyword | drug-eluting stent | - |
dc.subject.keyword | stent restenosis | - |
dc.subject.keyword | stent thrombosis | - |
dc.contributor.alternativeName | Im, Eui | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Im, Eui | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.citation.volume | 14 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 87 | - |
dc.citation.endPage | 104 | - |
dc.identifier.bibliographicCitation | EXPERT REVIEW OF CARDIOVASCULAR THERAPY, Vol.14(1) : 87-104, 2016 | - |
dc.date.modified | 2017-01-16 | - |
dc.identifier.rimsid | 47365 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.